FTC Extends Enforcement Date of Red Flags Rule to August 1
Client Alert | 1 min read | 05.04.09
On April 30th, in a surprising move, the Federal Trade Commission (the "FTC") extended its deferral of enforcement of the Red Flags Rule until August 1, 2009. This marks the second extension by the FTC. The Red Flags Rule's mandatory enforcement date was originally November 1, 2008. However, the FTC suspended enforcement of the Rule until May 1, 2009. The FTC explained that this second extension is in response to ongoing questions from some sectors - particularly smaller entities that are subject to a low risk of identity theft that "continue to have questions and concerns about the specific obligations they must meet and the burden of complying with the rule."1
The FTC has estimated that there are more than 1.6 million low-risk entities that will be required to comply with the Red Flags Rule.2 The Red Flags Rule requires that "financial institutions" and "creditors" that offer or maintain "covered accounts," develop and implement a program to identify, detect, and respond to identity theft (the "Program"). The FTC intends to publish a guidance to assist low-risk entities in complying with the rule.
If you are interested in learning more about Red Flags Rule policies, training, or sample language, please contact those listed below, or your regular Crowell & Moring contact.
1 FTC Extended Enforcement Policy: Identity Theft Red Flags Rule, 16 CFR 681.1
2 74 Fed. Reg. 18709, 18711 (April 24, 2009).
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
Client Alert | 4 min read | 10.20.26
California Follows New York’s Lead in Requiring AI “Synthetic Performer” Disclosures in Advertising
